Somatostatin modulators and uses thereof

Inventors

Zhao, Jian • Wang, Shimiao • ZHU, Yunfei

Assignees

Crinetics Pharmaceuticals Inc

Interested in licensing this patent?

MTEC can help explore whether this patent might be available for licensing for your application.

Publication Number

US-10875839-B2

Patent

Publication Date

2020-12-29

Expiration Date


Abstract

Described herein are compounds that are somatostatin modulators, methods of making such compounds, pharmaceutical compositions and medicaments comprising such compounds, and methods of using such compounds in the treatment of conditions, diseases, or disorders that would benefit from modulation of somatostatin activity.

Core Innovation

The disclosure relates to non-peptidyl small-molecule somatostatin receptor modulators, particularly somatostatin receptor subtype 2 modulators, comprising substituted cinnoline, quinoline, and naphthyridine compounds and related saturated heterocyclic derivatives. These structures encompass scaffolds represented by Formulas (A), (AI), (AII), (AIII), (A2), (I), (II), (III), (IIIb), (IV), (V), and (AV), along with pharmaceutically acceptable salts, solvates, stereoisomers, isotopically labeled compounds, prodrugs, and active metabolites.

The independent claim defines a method of treating acromegaly in a human by orally administering a pharmaceutical composition. This composition comprises a therapeutically effective amount of the specified compound, or a pharmaceutically acceptable salt or solvate thereof, and at least one pharmaceutically acceptable excipient. Furthermore, the claimed composition is formulated as a solid oral dosage form, specifically a tablet, a pill, or a capsule.

Functional assay characterization reports sub-10 nM EC50 activity for several disclosed compounds modulating somatostatin receptor subtype 2. The chemical series also includes aminated piperidines and octahydropyrido-morpholine analogs paired with varied aromatic or heteroaromatic groups. Because the background section is omitted from the supplied content, the specific technical problem being solved by the invention is not explicitly described in the patent.

Claims Coverage

The patent claims identify one independent claim directed to an oral method of treating acromegaly in a human, along with dependent claims specifying dosage forms and administration regimens. Four inventive features are disclosed.

Oral treatment of acromegaly

The independent claim provides a method of treating acromegaly in a human by orally administering a therapeutically effective amount of the specified compound, or a pharmaceutically acceptable salt or solvate thereof.

Pharmaceutical composition with excipient

The orally administered composition comprises a therapeutically effective amount of the specified compound, or a pharmaceutically acceptable salt or solvate thereof, and at least one pharmaceutically acceptable excipient.

Solid oral formulation

The independent claim specifies that the oral pharmaceutical composition is formulated in the form of a tablet, a pill, or a capsule.

Administration frequency and dosing regimens

Dependent claims define dosing regimens comprising administration once, twice, three times, or four times per day, including once-daily administration of a tablet or capsule.

The independent claim requires oral administration of a pharmaceutical composition comprising the specified active compound, salt, or solvate with an excipient in tablet, pill, or capsule form to treat human acromegaly, with dependent claims establishing specific daily administration frequencies.

Stated Advantages

Not explicitly described in patent.

Documented Applications

Treatment of acromegaly in a human by oral administration of the claimed pharmaceutical composition formulated as a tablet, pill, or capsule.

Treatment of other conditions benefiting from somatostatin modulation.

JOIN OUR MAILING LIST

Stay Connected with MTEC

Keep up with active and upcoming solicitations, MTEC news and other valuable information.